Cowen Financial Products Reports 1.91M Share Stake in Tarsus Pharma

TL;DR

**Cowen Financial Products owns 1.91M shares of Tarsus Pharma, showing a big institutional bet.**

AI Summary

Cowen Financial Products LLC, a Delaware-based entity, filed an amended SC 13G/A on February 2, 2024, disclosing its beneficial ownership in Tarsus Pharmaceuticals Inc. As of December 29, 2023, Cowen holds sole voting and dispositive power over 1,911,399 shares of Tarsus's Common Stock. This filing indicates a significant institutional stake, which can be a positive signal for investors as it shows a large financial entity has confidence in the company's prospects.

Why It Matters

This filing reveals a major institutional investor's updated position, signaling their continued or adjusted confidence in Tarsus Pharmaceuticals, which can influence market perception and other investors' decisions.

Risk Assessment

Risk Level: low — This filing is an update on an existing institutional ownership, which generally carries low risk as it doesn't indicate a sudden, drastic change in company fundamentals.

Analyst Insight

Investors should note Cowen Financial Products LLC's continued significant stake in Tarsus Pharmaceuticals Inc. as a potential indicator of institutional confidence, but should conduct further due diligence on Tarsus's fundamentals and market conditions before making investment decisions.

Key Numbers

• 1,911,399 — Shares Beneficially Owned (Represents the total number of Tarsus Pharmaceuticals Inc. common stock shares Cowen Financial Products LLC has sole voting and dispositive power over.)
• 87650L103 — CUSIP Number (Identifies the specific class of securities (Common Stock) of Tarsus Pharmaceuticals Inc. being reported.)
• December 29, 2023 — Event Date (The specific date that triggered the requirement for Cowen Financial Products LLC to file this Schedule 13G/A amendment.)

Key Players & Entities

• Cowen Financial Products LLC (company) — the reporting person beneficially owning shares of Tarsus Pharmaceuticals Inc.
• Tarsus Pharmaceuticals Inc. (company) — the issuer of the common stock being reported on
• 1,911,399 (dollar_amount) — the number of shares beneficially owned by Cowen Financial Products LLC
• December 29, 2023 (date) — the date of the event requiring the filing of this statement
• February 2, 2024 (date) — the filing date of the SC 13G/A amendment

Forward-Looking Statements

• Cowen Financial Products LLC will maintain a significant stake in Tarsus Pharmaceuticals Inc. for the foreseeable future. (Cowen Financial Products LLC) — medium confidence, target: December 29, 2024

FAQ

Filing Documents

• tarsa1_20224.htm (SC 13G/A) — 25KB
• 0001085146-24-000653.txt ( ) — 27KB

(a)

ITEM 1(a). NAME OF ISSUER: Tarsus Pharmaceuticals Inc.

(b)

ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: 15440 Laguna Canyon Rd. Irvine CA 92618

(a)

ITEM 2(a). NAME OF PERSON FILING: Cowen Financial Products LLC

(b)

ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: 599 Lexington Ave. New York NY 10022

(c)

ITEM 2(c). CITIZENSHIP: USA

(d)

ITEM 2(d). TITLE OF CLASS OF SECURITIES: Common Stock

(e)

ITEM 2(e). CUSIP NUMBER: 87650L103 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c); (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); (c) [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); (d) [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8); (e) [ ] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) [ ] Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution: ITEM 4. (a) Amount beneficially owned: 1,911,399 (b) Percent of class: 5.77% (c) Number of shares as to which the person has: (i) sole power to vote or to direct the vote: Cowen Financial Products LLC : 1,911,399 (ii) shared power to vote or to direct the vote: Cowen Financial Products LLC : (iii) sole power to dispose or direct the disposition of: Cowen Financial Products LLC : 1,911,399 (iv) shared power to dispose or to direct the disposition of: Cowen Financial Products LLC : ITEM 5. If this statement is being filed to report the fact that as of the da

View Full Filing

View this SC 13G/A filing on SEC EDGAR